scholarly journals Advanced Telemedicine Training and Clinical Outcomes in Type II Diabetes: A Pilot Study

2022 ◽  
Vol 3 (1) ◽  
pp. 15-23
Author(s):  
Colton B. Merrill ◽  
Jason M. Roe ◽  
Kevin D. Seely ◽  
Benjamin Brooks
2015 ◽  
Vol 50 (3) ◽  
pp. 243-259 ◽  
Author(s):  
Syam S. Andra ◽  
Harris Kalyvas ◽  
Xanthi D. Andrianou ◽  
Pantelis Charisiadis ◽  
Costas A. Christophi ◽  
...  

2019 ◽  
Vol 13 (1) ◽  
pp. 58-59
Author(s):  
Jessica McMaster ◽  
Graeme G. Rich ◽  
Linda Fletcher ◽  
Arjun Gandhi ◽  
Graeme Macdonald ◽  
...  

Stroke ◽  
2012 ◽  
Vol 43 (suppl_1) ◽  
Author(s):  
Sean S Li ◽  
Amy K Guzik ◽  
Brian H Annex ◽  
Bradford B Worrall

Background: Stroke is a leading cause of serious long-term adult disability in the United States. Hyperglycemia has consistently been associated with worse clinical outcomes from ischemic stroke. Animal studies utilizing genetic models of type II diabetes have shown greater ischemic injury in the setting of hyperglycemia. However, these models may not well represent all physiological aspects of human type II diabetes and post-stroke hyperglycemia. Diet induced diabetes may prove more analogous to human disease. The high fat diet mouse model of type II diabetes reliably creates a subacute hyperglycemic state. We evaluated normal and high fat diet (HFD) fed mice following middle cerebral artery occlusion (MCAO) to determine if post-ischemic functional status is influenced by hyperglycemia in this model. Methods: C57BL/6 male mice (12-18 weeks) fed either normal diet or HFD (60%kCal fat) were subjected to 60 minutes of transient MCAO via 6-0 monofilament. Triphenyltetrazolium chloride staining confirmed infarction in a subset of mice. A glucose tolerance test was performed, and fasting blood sugar was tested prior to surgery to verify hyperglycemia. Neurologic deficit score (NDS) was measured before and after surgery, and 24 hours post MCAO. Results: HFD fed mice demonstrated worse NDS following ischemia compared to normal fed mice. This was significant at 24 hours post MCAO (p<0.0001). Normal fed mice showed improvement in functional score 24 hours post MCAO (p<0.05), but HFD fed mice demonstrated no improvement. Conclusion: Our data show that HFD fed mice have worse outcomes post-MCAO and without the recovery in functional scores seen in normal fed mice. This mirrors the human condition, where worse clinical outcomes are seen in hyperglycemic patients with ischemic stroke. This model provides an opportunity to investigate mechanisms underlying differential recovery in the setting of hyperglycemia and to test if insulin treatment can prevent the adverse recovery in HFD animals as has been postulated in humans. We are conducting gene expression experiments to test candidates that may mediate ischemic damage and recovery and to identify novel therapeutic targets.


Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 4032-4032
Author(s):  
Patrick Van Dreden ◽  
Aurelie Rousseau ◽  
Thomas Exner ◽  
Marc Vasse ◽  
Geneviéve Ozenne ◽  
...  

Abstract Diabetes is associated with disturbances in haemostasis that are thought to result in an increased incidence of thrombotic complications and cardiovascular disease. The aim of this pilot study was to monitor activation of haemostasis using specific markers for platelet activation and coagulation. Plasma samples (all blood collected and plasma prepared in the same hospital under the same conditions) were obtained from twenty diabetic patients (8 with type I and 12 with type II) and twenty one normal control volunteers. To monitor coagulation these samples were evaluated with the partial thromboplastin time (APTT), prothrombin time (PT) and D-dimer (D-Di) - all reagents from Diagnostica Stago, Asniéres, France. Platelet activation was monitored with a novel method for monitoring procoagulant phospholipids microparticles (PPM) using a factor Xa-based coagulation assay. In this assay shortened clotting times are associated with increased levels of PPM and thus platelet activation. APTT Sec. PT % PPM Sec. D-Di μg/l Controls 34.6 (29.4–39.6) 93.1 (79–109) 57.5 (51.1–74.9) 0.22 (0.22–0.45) Type I Diabetes 34.5 (33.1–36.7) 96.9 (92–102.5) 33.8 (19.1–44.2) 1.6 (0.22–3.6) Type II Diabetes 36.8 (33.2–40.4) 96 (59.4–112.5) 48.3 (44.2–51.2) 0.7 (0.22–1.7) Significantly higher levels of both PPM and DD were found in Type I diabetes patients compared with controls (both P&lt;0.001). In type II diabetes the levels of both were lower than those found in Type I diabetes but both were still higher than the controls (PPM and DDi at p&lt;0.001 and p&lt;0.01 level respectively), only the differences in levels of PPM reaching significance between type I and type II diabetes (p&lt;0.01). The more severe the diabetes (type I &gt; type II) the greater the level activation of haemostasis that is observed. The increases in PPM could account in part for the development or progression of arthrosclerosis in patients with diabetes mellitus. The increased level of D-Di confirms the increased hypercoagulability of these patients. Although this was a small pilot study and further studies are needed to confirm these findings it is interesting to speculate on the usefulness of both the PPM assay and D-Di assays in monitoring the development/severity of diabetes and its complications. The PPM assay may prove to be especially useful in monitoring progression of the disease.


Sign in / Sign up

Export Citation Format

Share Document